See the FREE profile for ECYT NOW at Trade-Ideas More details on ECYT: Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Currently there are 6 analysts that rate Endocyte a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Endocyte has been 967,400 shares per day over the past 30 days. Endocyte has a market cap of $983.8 million and is part of the health care sector and drugs industry. The stock has a beta of 1.21 and a short float of 16.4% with 1.74 days to cover. Shares are up 135.6% year-to-date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.